Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 451 - 500 out of 17,604

Document Document Title
WO/2008/076904A9
The present invention provides novel peptidomimetic macrocycles and methods for their preparation and use, as well as amino acid analogs and macrocycle-forming linkers, and kits useful in their production.  
WO/2017/062990A1
A compound comprising formula (I): wherein R1 is an alkylamino group or a group containing at least one aromatic group; R2 and R3 are independently an aliphatic group or hydrophobic group; R4 and R5 are independently H, a substituted or ...  
WO/2017/060533A1
The subject matter of the present invention concerns a novel family of peptide conjugates of formula (I): A-X1-X2-Pro-Ala-X-B in which: - A is a hydrogen atom, a C6 to C20 acyl group or a cholesterol residue; - X1 is a covalent bond, an ...  
WO/2017/058808A1
Disclosed are compounds based on dolastatins, drug-conjugates, methods of preparing drug-conjugates, and uses thereof. Also disclosed are pharaceutical compositions and methods of treatment. The compounds and drug-conjugates disclosed he...  
WO/2017/054080A1
Compounds of general formula (I) having cytotoxic and/or anti-mitotic activity and methods of using such compounds, as well as pharmaceutical compositions comprising such compounds. The compounds may also be conjugated with a targeting m...  
WO/2017/050854A1
The present invention relates to the use of a cyclic peptide comprising the tripeptide reproducing a binding site of fertilin beta to the oocyte integrin, for improving cellular energy metabolism. More particularly, the invention concern...  
WO/2017/053864A1
The invention provides compounds and compositions that inhibit one or more cysteine proteases (e.g. caspases or cysteine cathepsins), as well as kits comprising such compounds and compositions. The invention also provides therapeutic met...  
WO/2017/049115A1
Methods and system for solid phase peptide synthesis are provided. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. New amino acid residues...  
WO/2017/047572A1
A heat-sensitive recording material obtained by forming a heat-sensitive recording layer, which contains a basic dye and a developer, on a supporting body. The developer is composed of at least one N-substituted amino acid derivative rep...  
WO/2017/045456A1
Disclosed is a cyclic peptide compound of a chemical structure as shown by general formula I, or a pharmaceutically acceptable salt, isomer, racemate, prodrug or solvate thereof. Compared with the positive control (SAHA), the compound ha...  
WO/2017/049165A1
The invention provides compounds and their pharmaceutical compositions according to Formula (I) that are useful for inhibiting RNA toxicity, such as in the treatment of myotonic dystrophy type 1, wherein W1, W2, W3, W4, L1, L2, and Cy ar...  
WO/2017/046323A1
The invention relates to a peptide, comprising (i) a main chain comprising at least one L-3,4-dihydroxyphenylalanine (DOPA), (ii) at least one integrin-binding peptide, and (iii) at least one heparin-binding peptide. The invention furthe...  
WO/2017/045063A1
The present invention relates to cyclic amino acid molecules, in particular 1,3,4-oxadiazole containing macrocyclic peptides, and a process to produce the same. The process involves the macrocyclization of amino acids or linear peptides....  
WO/2017/044592A1
Lipid-conjugated monovalent and bivalent secondary mitochondria derived activator of caspases (Smac) derivatives were synthesized and examined for in vitro and in vivo anticancer activity. Methods for treating cancer with these compounds...  
WO/2017/041403A1
The present invention provides a fluorescent probe substrate for determining an activity of dipeptidyl peptidase IV (DPP-IV) and a use thereof. The probe substrate is a C-4 amide derivative of naphthalimides, GPAN, and can be used to det...  
WO/2017/041733A1
Provided is a polypeptide that inhibits Aβ protein aggregation of Alzheimer's disease, and an amino acid sequence thereof is Xaa1-Xaa2-Xaa3-Xaa4. Xaa1 and Xaa3 are identical amino acids and selected from I, V or L, Xaa2 is selected from...  
WO/2017/040976A1
Disclosed are methods and compositions for selectively targeting sites of traumatic brain injury (TBI). A brain injury-specific 4-amino acid peptide (sequence CAQK), identified by in vivo phage display screening in mice with acute brain ...  
WO/2017/040304A1
Provided herein are compounds of Formula (I) and pharmaceutical compositions thereof, which may be useful as MALT1 inhibitors. Also provided are for the treatment of proliferative disorders (e.g., cancer (e.g., non-Hodgkin' s lymphoma, d...  
WO/2017/039726A1
Disclosed herein are novel HDAC inhibitors. The HDAC inhibitors may be used in methods of treating cancer. The HDAC inhibitors may be used in methods of treating a neurological disorder.  
WO/2017/033055A1
The present invention relates to novel cyclic peptidomimetics, pharmaceutical compositions containing them and their use in the treatment of diseases associated with angiogenesis especially tumors and chronic inflammation in psoriasis, d...  
WO/2017/032487A1
The present invention relates to compounds such as peptides which act as proteasome inhibitors. The compounds are covalently linked with a signal emitting compound or a precursor thereof, via an ester such as a sulfonic ester group for i...  
WO/2017/030814A1
The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by ...  
WO/2017/027967A1
The present application relates to a-substituted amino acid compounds of the Formula (I), compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions characterized by or ass...  
WO/2017/031209A1
The present disclosure relates to tubulysin derivatives and methods for making the same. The disclosure also relates to the use of such tubulysin derivatives in the preparation of drug conjugates of tubulysins.  
WO/2017/025802A1
Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.  
WO/2017/021004A1
The present invention relates to chromogenic and fluorogenic substrates that can be used for the highly sensitive and selective detection of the activity of serine proteases. The present invention further relates to methods for the detec...  
WO/2017/021904A1
The present invention relates to daclatasvir free base, processes for its preparation, a process for its conversion into pharmaceutically acceptable salts of daclatasvir. The present invention also relates to a process for the preparatio...  
WO/2017/023907A1
The present disclosure relates to phenyl urea derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N-formyl peptide receptor (FPR), such as agonism o...  
WO/2017/017445A1
The invention relates to peptoids, derivatives and analogues thereof, and to methods of chemically synthesising such compounds. The invention relates to mixed peptoids, derivatives and analogues thereof comprising lysine and arginine typ...  
WO/2017/013660A1
The present invention discloses a peptide capable of stabilizing mutation-induced GBE1 protein destabilization, conjugates comprising same and uses thereof for the treatment of diseases and disorders associate with glycogen storage.  
WO/2016/193954A3
The present invention describes the discovery of the genes that direct the biosynthetic pathway of leupeptin, a potent protease inhibitor of the type of small peptide aldehyde (SPA). The prediction of genes that direct the biosynthesis o...  
WO/2017/013172A1
The invention relates to inhibitors for p-glycoprotein, being compounds that comprise or consist of a tripeptide represented by the sequence XAB, wherein X, A, and B are 7amino acids, wherein X can be any amino acid and A and B are basic...  
WO/2017/011812A1
The present specification discloses modified APY cyclic peptides having EphA4 antagonistic activity, pharmaceutical compositions containing such EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or path...  
WO/2016/196124A3
The present invention relates to novel prodrugs of primary or secondary amine-comprising biologically active moieties and pharmaceutically acceptable salts thereof, prodrug reagents, pharmaceutical compositions comprising said prodrugs a...  
WO/2017/011826A1
Anti-lymphoma plant virus particles are described. The anti-lymphoma plant virus particles include a filamentous or rod-shaped plant virus particle linked to an antimitotic agent. A therapeutically effective amount of an anti-lymphoma pl...  
WO/2017/011582A1
The present disclosure provides assays for lysosomal enzymes, specifically palmitoyl protein thioesterase 1 (PPT1) and tripeptidyl peptidase 1 (TPP1), using, for example, tandem mass spectrometry. The assays involve the detection of enzy...  
WO/2017/005902A1
The present disclosure relates to methods of preparing and crystallizing β-turn cyclic peptidomimetic salts of formula (I): where R1, R2, R3, R4, R5, R6, R7, R8, R10, X, Y and n are as defined in the specification. The present disclosur...  
WO/2017/004811A1
Provided in the application are an active peptide for inhibiting an AMPA receptor and a preparation method and the use thereof. The preparation method for the active peptide comprises the following steps: 1) salmon skin is soaked and the...  
WO/2017/005547A1
The invention relates to a method for producing 2,6-bis(methionyl)-1,4-diketopiperazine comprising the following steps: a) heating a reaction mixture containing methionine and a polar protic solvent at a temperature of 145.0 to 169.5 °C...  
WO/2017/004396A1
A chewable delivery system for GSH comprised of a gum base and reduced glutathione, to supplement GSH during acute GSH depletion, and useful during acute GSH depletion produced by alcohol ingestion, and intense exercise. The blood alcoho...  
WO/2017/002765A1
Provided are: a calorie-reducing composition including a cyclic dipeptide or a salt thereof; and a food or beverage including said calorie-reducing composition. The cyclic dipeptide included in this calorie-reducing composition is effici...  
WO/2017/002895A1
Provided is a composition which has high absorbability in vivo and excellent biological safety, and which can enhance the angiotensin-converting enzyme inhibitory activity induced by amino acids. The ratio in the composition of the tot...  
WO/2016/206138A1
Provided are a compound for inhibiting a histone deacetylase (HDAC) and preparation method and use thereof. Provided is a compound represented by the following general formula, wherein a substituent group is defined as in the specificati...  
WO/2016/210294A1
Thienopyrrole compounds that may inhibit Oplophorus -derived luciferases are disclosed, as well as compositions and kits comprising the thienopyrrole compounds, and methods of using the thienopyrrole compounds.  
WO/2016/181408A3
The present invention relates to novel short-chain peptides of the general formula (I), which are selective and peripherally acting KOR agonist, their tautomeric forms, their enantiomers, their diastereoisomers, their stereoisomers, thei...  
WO/2016/205791A2
A body-weight support harness system is disclosed, including an improved body weight support system and method.  
WO/2016/204197A1
Provided are: a protein degradation inducing tag which is a molecule that has affinity with proteases and does not inhibit degradation of a protein by proteases; a protein degradation inducing molecule that is a conjugate of at least one...  
WO/2016/197190A1
In one aspect, the present invention relates to the crystal structure of Plasmodium vivax plasmepsin V in complex with an inhibitor, and to methods of using the crystal structure and related structural information to identify, design and...  
WO/2016/192149A1
A class of bis-alkoxyl amide alkyl cationic peptide lipids has a chemical structural formula: . After the bis-alkoxyl amide alkyl cationic peptide lipids are dispersed in water, a cationic peptide liposome that has desirable stability, u...  
WO/2016/193990A1
The application relates to peptide-based compounds of Formula I such as the compound of Formula II, methods of making such compounds, gels comprising such compounds, methods of making gels, methods of using such compounds for containing ...  

Matches 451 - 500 out of 17,604